

Daniel Rea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1101447/publications.pdf>

Version: 2024-02-01

7
papers

332
citations

1478505

6
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

602
citing authors

| # | ARTICLE | IF | CITATIONS |
|---|--|-----|-----------|
| 1 | Addressing overtreatment of screen detected DCIS; the LORIS trial. <i>European Journal of Cancer</i> , 2015, 51, 2296-2303. | 2.8 | 266 |
| 2 | Low grade Ductal Carcinoma in situ (DCIS): How best to describe it?. <i>Breast</i> , 2014, 23, 693-696. | 2.2 | 20 |
| 3 | Valuing the health states associated with breast cancer screening programmes: A systematic review of economic measures. <i>Social Science and Medicine</i> , 2019, 228, 142-154. | 3.8 | 13 |
| 4 | Six versus 12 monthsâ€™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190. | 2.8 | 11 |
| 5 | Valuing preferences for treating screen detected ductal carcinoma in situ. <i>European Journal of Cancer</i> , 2019, 123, 130-137. | 2.8 | 10 |
| 6 | Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. <i>Annals of Surgical Oncology</i> , 2017, 24, 566-567. | 1.5 | 9 |
| 7 | Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1014-1014. | 1.6 | 3 |